Skip to content

Public FDA record

K972307: ACCURUN 119 ANTI-HEPATITIS B E ANTIGEN (ANTI-HBE) POSITIVE CONTROL

510(k) clearance K972307 for Boston Biomedica, Inc.. View source facts, labeled dates, and the original FDA record.

FDA identifier
K972307
Company in FDA record
Boston Biomedica, Inc.
FDA decision date
Aug 7, 1997
First observed by MedTech Watch
Nov 16, 2026
Latest observed content change
Nov 17, 2026

Decision stated in the source

Substantially Equivalent

Source facts

Decision
Substantially Equivalent
Received
1997-06-19
Specialty
Clinical Chemistry
Decision code
SESE
Clearance type
Traditional

Source facts and excerpts are reproduced for research. Dates retain their source meanings. “First observed” describes collection, not FDA publication or product launch.

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 21, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 21, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 21, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗